__________________
Emerging Energy Technologies Summit
__________________
Guidelines
Timeline
Find a Team
Registration
Mentors
Presentation
Download PDF:
"Provisional Patent
Application" Packet
__________________
Fall 2007 Lectures
Register On-Line
Video Archives
__________________
Executive at Table
Leaders in Innovation
OnTheEdge Radio
Organizations
Join Our E-Mail List
|
Co-Founder, Partner
Hummer Winblad Venture Partners
Ann Winblad is the co-founding Partner of Hummer Winblad Venture Partners. She is a well-known and respected software industry entrepreneur and technology leader. Her background and experience have been chronicled in many national business and trade publications.
Ann has over 25 years of experience in the software industry. She began her career as a systems programmer at the Federal Reserve Bank. In 1976 Ann co-founded Open Systems, Inc., a top selling accounting software company, with a $500 investment. She operated Open Systems profitably for six years and then sold it for over $15 million. Prior to co-founding Hummer Winblad Venture Partners, Ann served as a strategy consultant for prestigious clients such as IBM, Microsoft, Price Waterhouse, and numerous start-ups. In addition, Ann has co-authored the book Object-Oriented Software and has written articles for numerous publications. Ann received a BA in mathematics and in business administration, as well as an MA in education and international economics from the University of St. Thomas, St. Paul, Minnesota. Ann also has an honorary Doctorate of Laws from the University of St. Thomas.
Ann has served as a Director of start-up and public companies and currently serves as a director of Voltage Security, Krillion and Mulesource. She is also a member of the Board of Trustees of the University of St. Thomas and is an advisor to numerous entrepreneur groups.
Click on photos for larger view:
CEO & President, Wize, Inc.
wize.com
http://tpatterson.typepad.com/tp/
Tom has held strategic positions at Procter and Gamble, PeopleSoft, and Respond.com. In his last operating role, he was the SVP of Technology Development and Operations for MarketTools where he managed them through 5 years of rapid growth. Most recently Tom was an Entrepreneur in Residence with the Mayfield Fund before joining Wize as CEO. Tom has earned a BS from Rensselaer Polytechnic Institute in Chemical Engineering as well as an MBA from Harvard Business School. Tom also sits on the Wize Board of Directors.
Click on photos for larger view:
Click on photos for larger view:
10:00 - 11:00 am
Marine Science Institute, Room 1302
Exchange ideas with one of the top 'energy future'
scientists!
The Technology Management Program, The Donald Bren School of Environmental
Science & Management; The Marine Science Institute and Engineers Without
Borders -- UCSB are pleased to present a morning discussion seminar with
Steven E. Koonin, Chief Scientist, British Petroleum.
Dr. Koonin will be visiting the UCSB campus on Thursday, March 8, 2007
and has generously
offered his time to meet with the UCSB community, faculty and students
who are interested in
discussing energy future issues.
Seating is Limited! Please RSVP to Vered Doctori vdoctori@bren.ucsb.edu.
About the Speaker:
The former provost at California Institute of Technology, a longtime
professor of theoretical
physics there, and the current chief scientist for British Petroleum
(BP), Dr. Koonin is the
second speaker in a four-part "Global Warming -- Science & Society"
lecture series presented
in collaboration with UCSB Arts & Lectures. He will discuss global
climate issues with a focus
on energy, which he describes as "one of the most important problems
facing society."
Dr. Koonin's Research Interests:
Earthshine: a phenomenon that allows the state of the earth's climate to
be monitored
by the brightness of sunlight reflected off the earth onto the dark part
of the lunar disk.
Theoretical nuclear, many-body, and computational physics.
Steven E. Koonin has served as chief scientist of BP, the world's second
largest independent
oil company, since 2004. BP refines and markets petroleum products in
more than 100 countries
and serves more than 13 million customers each day. As chief scientist,
Koonin is responsible
for BP's long-range technology plans and activities, particularly those "beyond petroleum." He
also has purview over BP's major university research programs around the
world and provides
technical advice to the company's senior executives. In 1975, he joined
the faculty of Caltech,
became a full professor in 1981, and served as Provost from 1995 to
2004. Koonin is a fellow of
the American Physical Society, the American Association for the
Advancement of Science, and
the American Academy of Arts and Sciences, as well as a member of the
Council on Foreign
Relations and the Trilateral Commission. He has served on numerous
advisory bodies for the
National Science Foundation, the U.S. Department of Defense, and the
Department of Energy
and its various national laboratories. His research interests have
included theoretical nuclear,
many-body, and computational physics, nuclear astrophysics, and global
environmental science.
Koonin received his B.S. in physics at Caltech and his Ph.D. in
theoretical physics from M.I.T.
State of California/Canada Trade Facts
- 626,000 California jobs are supported by Canada-U.S. trade
- Total Canada-U.S. merchandise trade: $411 billion
- Canada-U.S. trade supported 5.2 million U.S. jobs
- Trade with Canada supported more jobs in California than in any other
state.
- In 2004, bilateral Ca/Cda trade was valued at $28 billion or
almost $77 million per day.
Canada and the United States enjoy an economic partnership unique in the
contemporary world. We share the world's largest and most comprehensive
trading relationship, which supports millions of jobs in each country.
Since the implementation of the Canada-U.S. Free Trade Agreement in
1989, two-way trade has tripled. Under NAFTA, growth in bilateral trade
between Canada and the U.S. has averaged almost 6.0% annually over the
last decade. In 2004, bilateral trade with Canada was close to $680
billion, with over $1.5 billion worth of goods and services crossing the
border every day.
The Technology Management Program was pleased to present Matt Simmons,
Chairman and Chief Executive Officer of Simmons & Company International. Matt visited the UCSB campus on Wednesday, January 17th, 2007 and generously offered his time to meet with the UCSB community, faculty and students interested in discussing 'Peak Oil' and energy
future issues.
Simmons & Company International, is a Houston-based investment bank
that specializes in the energy industry.Mr. Simmons serves on the boards
of Brown-Forman Corporation, The Atlantic Council of The United States,
he's also a member of the National Petroleum Council and The Council
of Foreign Relations. Matt has an MBA from Harvard University and is a
highly sought after international keynote speaker. He is very frequently
invited as an expert to appear/comment in every major newspaper, network
TV broadcast and/or other media anytime the issue of energy is focused on.
For more information on Matthew Simmons please visit:
http://www.simmonsco-intl.com/research.aspx?Type=msspeeches
http://www.simmonsco-intl.com/
On June 13, the United States Supreme Court made a ground breaking decision in Merck v. Integra regarding the safety of using patented technologies for unpatented applications. The question in this case revolved around which types of experiments are ‘safe’ under the FDA Safe Harbor Rule 271(e)(1). Among other things, this ruling may effect when researchers may use patented research tools for their experiments.
On August 3rd, Gary Hansen, Associate Dean of the Technology Management Program at UC Santa Barbara hosted a discussion of a panel of experts considering the consequences that this ruling may have on bio-pharmaceuticals, bio-technology, and related intellectual property. The panel was composed of the following:
- Vern Norviel, Wilson, Sonsoni, Goodrich & Rosati
- Siegmund Gutman, Amgen, Inc.
- Jeffrey McKinney, Sheppard, Mullin
- Moderator: Sherylle Englander, Director, Sponsored Projects & Intellectual Property, Office of Research, UC Santa Barbara
At issue was experimentation and experimental use of patented inventions in the development of new drugs. The pure experimental use argument for non-infringement was abandoned on appeal in favor of a defense under the FDA Safe Harbor Rule 271(e)(1). Our panel examined the merits and implications of the June 13 ruling as it applies to Intellectual Property Law.
The Technology Management Program was proud to host this forum on cutting edge issues as part of our Leaders in Innovation series going on throughout the year. It is just one part of our ongoing program to give students, faculty and community members the tools to succeed in the technology fields that concern us all. Please visit our web site at WWW.TMP.UCSB.EDU to learn more about the Technology Management Program at UC Santa Barbara. If you would like to order a DVD of this or other events by Tech Management, please contact Gary Hansen at hansen@engineering.ucsb.edu.
View PDF
Ken Kosik (UCSB), Ben Reubinoff (Hadassah University Hospital), and
Dean MartinMoskovits (UCSB Sciences)
The promise and the business of human embryonic stem cell research.
Will stem cell research offer new pathways to treatment?
The University of California, Santa Barbara’s Technology Management Program and the department of Molecular, Cellular & Developmental Biology (MCDB) have cooperated to present a leading international stem cell researcher. Dr. Benjamin Reubinoff, Director of the Hadassah Human Embryonic Stem Cell Research Center, Israel. Reubinoff addressed UCSB faculty and invited guests on January 27, 2005 at The Engineering Science Building with the topic “The Promise of Human Embryonic Stem Cell Research”.
He leads a team from Israel's Hadassah University Hospital in Jerusalem which has used stem cells to treat rats with symptoms of Parkinson's Disease. Joel Rothman and Kenneth Kosik , Professor’s attached to MCDB led the q & a which followed the lecture.
Stem cells are capable of changing to form different cells with a wide variety of functions throughout the body. This experiment indicated that the stem cells developed into the nerve cells which had previously been lost through Parkinson's. This was the first time human stem cells had proved an effective treatment in animals. The rats' behavior changed after their treatment. The progressive decline associated with Parkinson's Disease is caused by a loss of brain cells which produce a chemical called dopamine. When post-mortem examinations were carried out on the rats, it was found that the stem cells had developed into dopamine-producing cells. Reubinoff, who led the study, said “We believe that these observations are encouraging, and set the stage for future development that may eventually allow the use of embryonic stem cells for the treatment of Parkinson's disease in humans."
However, he said “further studies would be needed before the treatment could be given to humans because the safety of the treatment could not yet be assured.”
US companies using existing stem cell lines include BioTransplant, Aastrom Biosciences (Nasdaq:ASTM), StemCells Inc. (Nasdaq:STEM), OrganoGenesis (AMEX:ORG) and Nexell Therapeutics (Nasdaq:NEXL).
Hadasit Medical Research Services and Development promotes and markets the intellectual property generated by the Hadassah Medical Organization. Israeli start-up Embryonic Stem Cell International (ESI) was founded in July 2001, just before the official NIH policy directive on stem cell research. ESI developed out of research by Dr. Reubinoff, and three colleagues from Australia, the Netherlands and Singapore. The researchers developed a technique to develop embryonic stem cells from surplus embryos, “in order not to waste them”. ESI’s discovery earned it a $10 million investment, at a $20 million company value, from Life Science Investments of Singapore and ES Cell Australia Pty Ltd. ESI’s first market is a treatment for Parkinson’s disease, and the company is trying to develop stem cells for the pancreas and heart. ESI has signed a development agreement with Quark Biotech (QBI) to use QBI’s proprietary technology platform to discover new genes such as growth and cell differentiation factors derived from embryonic stem cells.
View PDF
TMP 'Founder' Supporters
 |
|
_______________________________________________________________________________
Director Level Supporter
|
|
Thursday, March 8, 2007 
